4I5C

The Jak1 kinase domain in complex with inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.190 
  • R-Value Observed: 0.193 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.

Hurley, C.A.Blair, W.S.Bull, R.J.Chang, C.Crackett, P.H.Deshmukh, G.Dyke, H.J.Fong, R.Ghilardi, N.Gibbons, P.Hewitt, P.R.Johnson, A.Johnson, T.Kenny, J.R.Kohli, P.B.Kulagowski, J.J.Liimatta, M.Lupardus, P.J.Maxey, R.J.Mendonca, R.Narukulla, R.Pulk, R.Ubhayakar, S.van Abbema, A.Ward, S.I.Waszkowycz, B.Zak, M.

(2013) Bioorg Med Chem Lett 23: 3592-3598

  • DOI: 10.1016/j.bmcl.2013.04.018
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in c ...

    The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in cells and higher oral exposure in rat than the corresponding, previously reported, imidazo-pyrrolopyridine analogue 2. Examples 6, 7 and 18 were subsequently identified from an optimization campaign and demonstrated modest selectivity over JAK2, moderate to good oral bioavailability in rat with overall pharmacokinetic profiles comparable to that reported for an approved pan-JAK inhibitor (tofacitinib).


    Organizational Affiliation

    Department of Medicinal Chemistry, Argenta, 8/9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom. Chris.Hurley@glpg.com



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase JAK1A, B302Homo sapiensMutation(s): 0 
Gene Names: JAK1JAK1AJAK1B
EC: 2.7.10.2
Find proteins for P23458 (Homo sapiens)
Explore P23458 
Go to UniProtKB:  P23458
NIH Common Fund Data Resources
PHAROS  P23458
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
C5I
Query on C5I

Download CCD File 
A, B
3-oxo-3-[(3R)-3-(pyrrolo[2,3-b][1,2,3]triazolo[4,5-d]pyridin-1(6H)-yl)piperidin-1-yl]propanenitrile
C15 H15 N7 O
COGIAVJREKAVDL-SNVBAGLBSA-N
 Ligand Interaction
EDO
Query on EDO

Download CCD File 
B
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
A,BL-PEPTIDE LINKINGC9 H12 N O6 PTYR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
C5IKi:  1.5   nM  Binding MOAD
C5IEC50:  114   nM  BindingDB
C5IKi:  1.5   nM  BindingDB
C5IKi :  1.5   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.190 
  • R-Value Observed: 0.193 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 42.7α = 90
b = 173.969β = 94.11
c = 44.675γ = 90
Software Package:
Software NamePurpose
Blu-Icedata collection
PHASERphasing
BUSTERrefinement
XDSdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-05-22
    Type: Initial release
  • Version 1.1: 2013-06-12
    Changes: Database references